biomarker discovery
Cofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain Spinout
Premium
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.
The firm reported Thursday its Q1 revenues declined 30 percent as COVID-19 revenues dwindled but non-COVID organic revenues grew 6 percent.
Companies that built their business in tissue and blood-based DNA analyses are now exploring imaging technologies across a variety of fronts.
Micronoma, University of New South Wales to Develop Liver Cancer Dx Using $4M Grant
University researchers will use the firm's platform to analyze microbiome biomarkers to develop a noninvasive early detection method for hepatocellular carcinoma.
Valted Seq Lands Exclusive Rights to Evaluate Johns Hopkins Neurodegenerative Disease Dx Assays
The biomarker assays could one day be used as companion diagnostics for new treatments of Parkinson's and related diseases.